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ABSTRACT
Objective: The objective of this study is to alter the expression of p-glycoprotein (p-gp) pump proteins in HepG2 cells after treating with urea 
and β-mercaptoethanol (BME) (lead compounds). The most common cause for resistance to a broad range of anticancer drugs is influenced by 
overexpression of p-gp pumps that detect and eject anticancer drugs from the cancer cell. Altering the expression of these proteins will reduce the 
efflux action and enhance the drug retention eventually killing the cancer cell.
Materials and Methods: 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyl tetrazolium bromide (MTT) assay was carried out to measure the cell viability 
(HepG2 cells) post-treatment with the lead compounds followed by flow cytometric analysis for protein expression studies.
Results: MTT assay confirms that the viability of HepG2 cells reduces as the concentrations of the lead compounds are increased. Flow cytometric 
analysis confirms reduced p-gp expression in HepG2 cells post-treatment with urea and BME. Compare to BME, urea turns out to be a potential 
compound in altering the expression of p-gp.
Conclusion: The present cell line study confirms that urea and BME are potential compounds which are able to reduce the p-gp expression in 
HepG2 cells.
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INTRODUCTION
The most common cause of resistance to a broad range of anticancer 
drugs is influenced by the expression of energy-dependent transporters 
that detect and eject anticancer drugs from cells. The members of the 
ATP-binding cassette transporters are highly involved in this process. 
Till date, 49 such members have been identified in humans. There are 
two functional domains present for these transporters. These domains 
include a highly conserved nucleotide binding domain and a variable 
transmembrane domain [1]. These pumps also have a substrate 
binding site which is facing toward the cytosolic face. On binding, the 
substrate hydrolysis of ATP at the nucleotide-binding site induces a 
conformational change in these pumps which induces the efflux action, 
thus driving the substrate out from the cytoplasm to the surrounding 
matrix. Under normal condition, these pumps are highly essential as they 
drive out toxins from the cell which may otherwise cause detrimental 
effects [2]. These pumps are predominant in our liver epithelium and 
intestinal epithelium where they are meant for pumping out the drugs 
and harmful molecules into the bile duct and intestinal lumen, thus 
protecting our body from adverse effects. Maintenance of blood-brain 
barrier also comes under the influence of these pumps [3,4].
As a part of the normal physiological function, these pumps are meant 
for efflux action. Expression of these p-gp pumps increases when the 
tissues turn neoplastic. The overexpression is induced by intrinsic 
factors and acquired mechanism, i.e., on exposure to chemotherapeutic 
drugs [5]. Once these pumps are overexpressed, they are responsible 
for pumping the chemotherapeutic drugs outside the cell and thus 
inducing multidrug resistance (MDR). There are three types of 
transporters – MDR protein 1 (MDR1), MDR-associated protein 1 
(MRP1), and breast cancer resistance protein (BCRP) – which are 
involved in drug resistance. All the three transporters are highly specific 
for their substrates which include a wide range of chemotherapeutic 
drugs such as vinca alkaloids, epipodophyllotoxins, anthracyclines, 
taxanes, and kinase inhibitors. MDR1 gene produces p-glycoprotein 
(p-gp) predominates in colon, liver, and kidney cells [6-8]. The tissues 
which do not express MDR1 (lung, breast, and prostate cells) become 
resistant to chemotherapeutic drugs due to overexpression of MRP1 
and BCRP [9,10].
Various techniques have been adopted to deactivate these pumps. 
In virtual screening, computational models are used to predict the 
biological activity of various compounds. In a study by Kumar et al., 
a series of pyrrolopyrimidines were considered for ligand-based 
pharmacophore modeling to inhibit p-gp function [11]. In another 
study by Laksmiani et al. (2017) demonstrated molecular docking of 
brazilein (induced growth inhibition in breast cancer cells) to p-gp 
in the ATP-binding site. The interaction happens through hydrogen 
bonding between O atom in the carbonyl group of C9 atom of brazilein 
with H atom in Ser 423, Leu 504, and Asp 505 amino acid residues of 
p-gp protein [12].
Most efforts to inhibit p-gp have focused on the identification of 
modulator compounds that inhibit p-gp activity during chemotherapy. 
A good number of chemicals inhibit or deactivate p-gp and thus reverse 
MDR. Most of them are effective in vitro but have an adverse effect 
on the hosts. Some of these inhibitors have been non-selective, less 
potent with a reduced half-life period. In this current study, instead of 
deactivating the pump with an inhibitor native form of p-gp has been 
targeted using denaturing agent urea and β-mercaptoethanol (BME). 
Altering the native form will hinder its biological function and thus 
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help in overcoming chemotherapeutic drug resistance. Urea is used 
to break non-covalent bonds, i.e., hydrogen bonds. BME, a disulfide 
reducing agent, can covalently interact with specific protein functional 
groups [13]. This chemical cocktail is ideally used for unfolding 
membrane proteins. Urea does not disrupt the membrane itself but 
helps to solubilize the hydrophobic membrane protein in water [14]. 
The misfolded protein does not reach the cell surface and is retained 
in the endoplasmic reticulum followed by rapid degradation. Unfolded 
pump proteins which cannot be expressed in the cell surface, will allow 
the chemotherapeutic drug retention in cancer cells which otherwise 
pump out the drugs from the cell into the matrix, thus gaining 
chemotherapeutic resistance.
In silico analysis by Kumar et al. proved that urea and BME can bind 
to p-gp with the best docking scores of −15.5995 and −10.0501, 
respectively. Binding of BME caused a considerable perturbation 
in the backbone of the target with RMSD value eventually deviating 
to approximately 1.3 and urea further deviate the value to 
approximately 1.6. Furthermore, the decrease in the intramolecular 
hydrogen bonds over the simulation period confirms the secondary 
structural change [15].
MATERIALS AND METHODS
Determination of cytotoxicity (MTT assay)
The monolayer HepG2 cell culture in T25 flask was trypsinized and 
the cell count was adjusted, using DMEM (Dulbecco’s Modified Eagle’s 
Medium) containing fetal bovine serum such that 200 μl of suspension 
contains approximately 20,000 cells. 200 μl of cell suspension was 
seeded in a 96-well plate at required cell density (20,000 cells per 
well), without the test compounds (urea and BME). The cells were 
allowed to grow for about 24 h. After 24 h, when a partial monolayer 
was formed, the exhausted media was aspirated and 200 μl of different 
concentrations ranging from 5 uM to 200 uM of test compounds were 
added. The controlled wells were treated only with the media without 
the test compounds. The plate was incubated for 24 h at 37°C in a 5% 
CO2 atmosphere. After the incubation period, the plates were taken 
out from incubator, and the spent media containing test compounds 
were removed and 100 µl 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyl 
tetrazolium bromide (MTT) reagent was added to a final concentration 
of 0.5 mg/ml of total volume. The plate was kept incubated for 2 h in 
a CO2 incubator. MTT reagent was removed and 100 μl of dimethyl 
sulfoxide (DMSO) was added. Initially, the solution was yellow due to 
MTT as DSMO was added the purple crystals solubilized in it giving 
a purple color solution. The plate was incubated for 10 min before 
taking the OD readings. The absorbance reading was taken on an ELISA 
reader using 570 nm and 630 nm as reference wavelength followed 
by percentage calculation for cell viability [16-18]. % of cell viability 
= (Absorbance of treated cells/absorbance of control cells) ×100. 
GraphPad Prism software was used for plotting the MTT assay graph 
(concentration vs. cell viability) and P value was calculated.
Protein expression study (flow cytometric analysis)
Cells were cultured in a 6-well plate at a density of 3 × 105 cells/2 ml 
and incubated in a CO2 incubator overnight at 37°C for 24 h. The spent 
medium was aspired out and the cells were treated with 50 uM, 100 uM, 
and 150 uM concentrations of experimental compounds (urea and 
BME) and to the controlled well only 2 ml media were added followed 
Fig. 1: Graph showing the effect of urea and β-mercaptoethanol (BME) on HepG2 cell viability (n = 3) (a) Cytotoxicity versus concentration 
of urea (P = 0.0048). (b) Cytotoxicity versus concentration of BME (P = 0.003)
a b
Fig. 2: 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyl tetrazolium 
bromide assay – Cell viability by 3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyl tetrazolium bromide assay after 24 h treatment with 
urea and β-mercaptoethanol (BME). (a) Untreated HepG2 cells.  
(b) HepG2 cells treated with 5 uM concentration of urea.  
(c) HepG2 versus 50 uM urea. (d) HepG2 versus 100 uM urea.  
(e) HepG2 versus 150 uM urea. (f) HepG2 versus 200 uM urea. 
 (g) HepG2 versus BME-5 uM. (h) HepG2 versus BME-50 uM.  
(i) HepG2 versus BME-100 uM. (j) HepG2 versus BME-150 uM.  
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reduced oxidative stress may be one reason why BME is ineffective 
to p-gp expression at higher concentration. Chemotherapy would 
be much more effective if p-gp pumps were shut down during 
the treatment. Most efforts to inhibit p-gp have focused on the 
identification of modulator compounds that inhibit p-gp activity 
during chemotherapy. In earlier studies, resistance modifying 
agent oxalyl bis (N-phenyl) hydroxamic acid (OPHA) has been used 
to inhibit p-gp. The high IC50 values of OPHA against different cell 
lines indicate the non-toxic nature of the compound. It has also been 
tested in mice model, but its exact effect on the human in vivo has 
not been confirmed [24]. There are some pharmacological agents 
who showed low protein affinities; others are nonselective and less 
potent. In this current study, urea and BME have been used to alter 
the native form of p-gp. Comparative analyses of the effect of urea 
and BME on p-gp expression have been depicted in Fig. 7. Urea is one 
of the endogenous compounds of the body with a normal range of 
2.5–7.1 mmol/L. In one of the studies by Clark et al., oral dose of urea 
has been used in the treatment of secondary tumors in the liver. Urea 
was administered at a total dose of 8 gm−2 in divided doses 4 times 
daily. Although the treatment was ineffective against metastatic liver, 
by incubation for 24 h. The treated media were removed from the 6-well 
plate after 24 h and 1 ml phosphate-buffered saline (PBS) was added 
to wash the cells followed by addition of 300 µl trypsin for 3–5 min. 
After 5 min, 1 ml low glucose media were added and the cell suspension 
was transferred into a centrifuge tube and centrifugation was done at 
2000 rpm for 5 min. The supernatant was discarded and to the cell 
pellets, 5 µl of anti-p-gp was added and the tubes were incubated for 
30 min in a dark environment. After the incubation period, 500 µl of 
PBS was added in all the tubes, the content was mixed well and then 




The result of in vitro cytotoxicity study in HepG2 cell line reveals 
that both urea and BME is cytotoxic at higher concentration. The 
concentrations used for this study ranges from 5 uM to 200 uM. In a 
comparatively lower dose, the cells were surviving but as we increased, 
the concentration cell death was visible. This indicates that the cytotoxic 
effect was dose dependent (Figs. 1 and 2).
Flow cytometry
Urea and BME-treated HepG2 cells were subjected to flow cytometric 
analysis for protein expression studies (p-gp). Three different 
concentrations were chosen for analysis 50 uM, 100 uM, and 150 uM. 
As the concentration of the target compound – urea increases the native 
form of p-gp are altered and the surface isotopes are displaced. Anti-Pgp 
cannot bind to such displaced isotopes, thus p-gp mean fluorescence 
intensity decreases. Flow cytometric graph clearly indicates that 
untreated HepG2 cells are showing high p-gp expression with the 
histogram toward the M2 zone and as the concentration of urea increases 
the protein expression decreases as a result of which the histogram 
being gradually shifted toward the M1 zone (Figs. 3 and 4). However, in 
the case of BME-treated cells, 50 uM concentration is showing a change 
in protein expression, but as the concentration increases, there is no 
such decrease in the expression levels of p-gp (Figs. 5 and 6).
DISCUSSION
An earlier study indicates that BME reduces oxidative stress and 
has a growth promoting action on mouse lymphoma L1210 cells in 
vitro [22]. Maintaining low levels of protein oxidation are, therefore, 
a key part of balanced protein expression in the cells [23]. Thus, 
Fig. 4: Overlaid expression of PGP-PE in the untreated HepG2 
Cells (green curve) and test compound urea-treated cells at 
different concentrations. The untreated cells are showing a 
higher expression of p-glycoprotein but as the concentration of 
urea is increased the expression level of p-glycoprotein gradually 
decreases
Fig. 3: PGP expression (PGP-PE) study on HepG2 cells after treating with test compound urea. PGP-PE histogram of the gated 
HepG2 singlets distinguishes cells at the M1 and M2 phases. Here, M2 refers to high expression/region and M1 refers to the low 
expression/region of p-glycoprotein. (a) Untreated cells. (b) Cells treated with 50 µM concentration of urea. (c) Cells treated with 100 µM 




Asian J Pharm Clin Res, Vol 12, Issue 6, 2019, 284-288
 Chakraborty et al. 
tumor plasma urea concentration was not affected. All the patients 
tolerated urea without any toxicity [25]. Anticancer property of BME 
has already been reported [26]. If urea and BME are specifically 
targeted against overexpressed p-gp in cancer cells, it may alter the 
native state, thus hindering its efflux action.
CONCLUSION
In this study, HepG2 cells are treated with urea and BME to alter 
the native form of p-gp. An altered form of p-gp would not be able 
to express itself on the cell surface. Without the active pump 
protein (p-gp), the cancer cell will retain the anticancer drugs which 
are otherwise being thrown out of the cell due to the efflux action. 
Conjugating urea and BME with a potential anticancer drug and its 
specific targeting to cancer cell can help in overcoming the property of 
multidrug resistance. Urea and BME can alter the p-gp expression and 
the anticancer drug can eventually kill the target cell without causing 
damage to the normal ones. Hence, the present study could be the 
basis for the development of novel methods for prevention of MDR in 
the cancer cell.
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